199 related articles for article (PubMed ID: 26216729)
1. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Reyners AKL; de Munck L; Erdkamp FLG; Smit WM; Hoekman K; Lalisang RI; de Graaf H; Wymenga ANM; Polee M; Hollema H; van Vugt MATM; Schaapveld M; Willemse PHB;
Ann Oncol; 2012 Nov; 23(11):2896-2902. PubMed ID: 22689176
[TBL] [Abstract][Full Text] [Related]
3. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
[TBL] [Abstract][Full Text] [Related]
4. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.
Wade KNS; Brady MF; Thai T; Wang Y; Zheng B; Salani R; Tewari KS; Gray HJ; Bakkum-Gamez JN; Burger RA; Moore KN; Bookman MA
Gynecol Oncol; 2019 Oct; 155(1):69-74. PubMed ID: 31409486
[TBL] [Abstract][Full Text] [Related]
5. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Lesnock JL; Farris C; Krivak TC; Smith KJ; Markman M
Gynecol Oncol; 2011 Sep; 122(3):473-8. PubMed ID: 21665250
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
von Gruenigen VE; Huang HQ; Beumer JH; Lankes HA; Tew W; Herzog T; Hurria A; Mannel RS; Rizack T; Landrum LM; Rose PG; Salani R; Bradley WH; Rutherford TJ; Higgins RV; Secord AA; Fleming G
Gynecol Oncol; 2017 Mar; 144(3):459-467. PubMed ID: 28089376
[TBL] [Abstract][Full Text] [Related]
7. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
[TBL] [Abstract][Full Text] [Related]
8. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM; Siegel ER; Buza N; Bellone S; Silasi DA; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Rao GG; Reader JC; Hui P; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Santin AD
Br J Cancer; 2022 Jun; 126(12):1695-1703. PubMed ID: 35149854
[TBL] [Abstract][Full Text] [Related]
9. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Grabosch S; Tseng G; Edwards RP; Lankes HA; Moore K; Odunsi K; Vlad A; Ma T; Strange M; Brozick J; Lugade A; Omilian A; Bshara W; Stuckey AR; Walker JL; Birrer M
Gynecol Oncol; 2017 Jul; 146(1):137-145. PubMed ID: 28483269
[TBL] [Abstract][Full Text] [Related]
10. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Sia TY; Tew WP; Purdy C; Chi DS; Menzin AW; Lovecchio JL; Bookman MA; Cohn DE; Teoh DG; Friedlander M; Bender D; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray HJ; Secord AA; Van Le L; Lichtman SM
Gynecol Oncol; 2023 Jun; 173():130-137. PubMed ID: 37148580
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Moore KN; Tritchler D; Kaufman KM; Lankes H; Quinn MCJ; ; Van Le L; Berchuck A; Backes FJ; Tewari KS; Lee RB; Kesterson JP; Wenham RM; Armstrong DK; Krivak TC; Bookman MA; Birrer MJ
Gynecol Oncol; 2017 Nov; 147(2):396-401. PubMed ID: 28935272
[TBL] [Abstract][Full Text] [Related]
12. c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.
Morgan RD; Ferreras C; Peset I; Avizienyte E; Renehan AG; Edmondson RJ; Murphy AD; Nicum S; Van Brussel T; Clamp AR; Lambrechts D; Zhou C; Jayson GC
BMC Med; 2022 Feb; 20(1):59. PubMed ID: 35144591
[TBL] [Abstract][Full Text] [Related]
13. Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
Fuh KC; Java JJ; Chan JK; Kapp DS; Monk BJ; Burger RA; Young RC; Alberts DS; McGuire WP; Markman M; Bell J; Ozols RF; Armstrong DK; Aghajanian C; Bookman MA; Mannel RS
Gynecol Oncol; 2019 Aug; 154(2):420-425. PubMed ID: 31229298
[TBL] [Abstract][Full Text] [Related]
14. Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.
Phelps DL; Borley JV; Flower KJ; Dina R; Darb-Esfahani S; Braicu I; Sehouli J; Fotopoulou C; Wilhelm-Benartzi CS; Gabra H; Yazbek J; Chatterjee J; Ip J; Khan H; Likos-Corbett MT; Brown R; Ghaem-Maghami S
Br J Cancer; 2017 May; 116(10):1287-1293. PubMed ID: 28350786
[TBL] [Abstract][Full Text] [Related]
15. Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis.
Hilal Z; Rezniczek GA; Klenke R; Dogan A; Tempfer CB
J Gynecol Oncol; 2017 Nov; 28(6):e80. PubMed ID: 29027398
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
Kahn RM; Ragupathi G; Zhou QC; Iasonos A; Kravetz S; Hensley ML; Konner JA; Makker V; Tew WP; Aghajanian C; Sabbatini PJ; O'Cearbhaill RE
Cancer Immunol Immunother; 2023 Jan; 72(1):183-191. PubMed ID: 35779095
[TBL] [Abstract][Full Text] [Related]
17.
Thiel KW; Devor EJ; Filiaci VL; Mutch D; Moxley K; Alvarez Secord A; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Aghajanian C; Samuelson MI; Lankes HA; Soslow RA; Leslie KK
J Clin Oncol; 2022 Oct; 40(28):3289-3300. PubMed ID: 35658479
[TBL] [Abstract][Full Text] [Related]
18. Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).
Donovan HS; Sereika SM; Wenzel LB; Edwards RP; Knapp JE; Hughes SH; Roberge MC; Thomas TH; Klein SJ; Spring MB; Nolte S; Landrum LM; Casey AC; Mutch DG; DeBernardo RL; Muller CY; Sullivan SA; Ward SE
J Clin Oncol; 2022 May; 40(13):1464-1473. PubMed ID: 35130043
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of moderate or massive ascites in patients with advanced gastric cancer.
Iwai N; Ohara T; Okuda T; Oka K; Sakai H; Kajiwara-Kubota M; Tsuji T; Sakagami J; Kagawa K; Doi T; Inoue K; Dohi O; Yoshida N; Uchiyama K; Ishikawa T; Takagi T; Konishi H; Itoh Y
Oncol Lett; 2024 Mar; 27(3):116. PubMed ID: 38312910
[TBL] [Abstract][Full Text] [Related]
20. [Large number of immature granulocytes in ascites caused by granulocyte colony-stimulating factor after chemotherapy for ovarian cancer: report of a case].
Guo XL; Lu J; Qiao XY; Xi YF
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):504-506. PubMed ID: 38678338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
